Lakewood-Amedex Announces Exciting Leadership Transition
In a significant development, Lakewood-Amedex Inc. has welcomed Douglas Manion, M.D., FRCP (C), as the new Chairman of the Board of Directors. Dr. Manion, who joined the board in 2021, also serves as the Chief Executive Officer of Flare Therapeutics, bringing a wealth of experience to his new role.
Executive Promotions Strengthen Leadership Team
In addition to Dr. Manion's appointment, the organization has elevated Kelvin Cooper, Ph.D., C.Chem., FRSC, to Chief Executive Officer. Dr. Cooper, who previously performed brilliantly as the Chief Operating Officer and Senior Vice President of Research and Development, steps into a pivotal position for the company’s future. Alongside him, Peter Ceccacci has been promoted to Chief Financial Officer, enhancing the leadership dynamics with his extensive background in finance.
Dr. Manion's Vision for Growth
Expressing his enthusiasm, Dr. Manion stated, "As Chairman, I look forward to working with our leadership team to propel our Bisphosphocin® portfolio, aiming to tackle the critical challenge of antimicrobial resistance. With such capable individuals at the helm, our mission seems more attainable. We aim for remarkable advancements in Research and Clinical Development programs as we tackle diverse clinical needs worldwide.”
A Leader with Robust Background
Before joining Lakewood-Amedex, Dr. Manion gained significant experience as the Chief Executive Officer of Aclaris Therapeutics and held crucial roles at Arena Pharmaceuticals. His journey in the pharmaceutical realm includes top positions at Bristol Myers-Squibb, where he influenced research and development in various essential areas. With board certifications in Internal Medicine and specialized training in Infectious Diseases, Dr. Manion embodies the expertise necessary for leading a clinical-stage pharmaceutical company.
Kelvin Cooper: A Pillar of Experience
Dr. Cooper, now at the forefront as CEO, brings more than 45 years of rich experience in drug discovery and development across various therapeutic domains. His notable tenure at Pfizer, where he held senior leadership roles, showcases his deep knowledge in driving successful pharmaceutical initiatives. His academic achievements, including a Ph.D. in Organic Chemistry, complemented by numerous publications and patents, further solidify his credentials within the industry.
Peter Ceccacci's Financial Expertise
In concert with Dr. Cooper, Peter Ceccacci steps into his role as Chief Financial Officer, armed with over 30 years of experience in financial leadership across multiple sectors. His previous roles in public accounting and executive finance demonstrate his capability to navigate complex financial landscapes. Mr. Ceccacci's background serves Lakewood-Amedex well, ensuring that financial strategies align closely with the company’s overarching goals for growth and innovation.
About Lakewood-Amedex
Lakewood-Amedex, Inc. stands as a beacon in the clinical-stage pharmaceutical industry, dedicated to developing a groundbreaking portfolio of antimicrobial and antifungal therapeutics under the Bisphosphocin® category. With a strong foundation supported by an extensive patent portfolio, their innovative products are progressing through clinical evaluations. The company's lead candidates are engineered to address the pressing concerns associated with antibiotic resistance, as they have already demonstrated efficacy in combating various bacterial and fungal strains tested.
Frequently Asked Questions
Who is the new Chairman of Lakewood-Amedex's Board?
The new Chairman is Douglas Manion, M.D., FRCP (C), who brings extensive experience from his prior roles.
What leadership changes have occurred at Lakewood-Amedex?
Alongside Dr. Manion's appointment as Chairman, Kelvin Cooper has been promoted to CEO, and Peter Ceccacci is now CFO.
What are Dr. Manion's goals as Chairman?
Dr. Manion aims to advance the Bisphosphocin® portfolio and tackle antimicrobial resistance through innovative research and development efforts.
What is Lakewood-Amedex known for?
Lakewood-Amedex focuses on developing first-in-class antimicrobials and antifungals under the Bisphosphocin® class to address urgent healthcare needs.
How has Dr. Cooper's experience shaped his role as CEO?
Dr. Cooper's extensive background in drug discovery and development positions him effectively to lead Lakewood-Amedex in achieving its objectives.
